Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a research note issued on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Other analysts have also recently issued reports about the company. Morgan Stanley lifted their price target on Intra-Cellular Therapies from $92.00 to $95.00 and […]
StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a research note issued on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Other analysts have also recently issued reports about the company. Morgan Stanley lifted their price target on Intra-Cellular Therapies from $92.00 to $95.00 and […]